The Mesoblast Ltd (ASX: MSB) share price is focus today after the company reported a surge in revenue to US$51.3 million, thanks to the successful commercial launch of Ryoncil® in the US.
Image source: Getty Images
What did Mesoblast report?
- Total revenue jumped to US$51.3 million (A$78.3 million), up from US$3.2 million in the previous period.
- Ryoncil® gross profit (excluding amortisation) was US$44.2 million versus nil a year ago.
- Net loss narrowed to US$40.2 million from US$47.9 million, an improvement of US$7.8 million.
- Net operating cash spend was US$30.3 million, with expectations for further reduction in the second half.
- cash and cash equivalents stood at US$130 million at period end.
- Mesoblast provided net revenue guidance for FY2026 of US$110 million to US$120 million.
What else do investors need to know?
Mesoblast's growth is being driven by its flagship product Ryoncil®, which launched commercially in the US and is now covered by government and commercial payers representing around 280 million Americans. Forty-nine transplant centres have been onboarded, with the aim to reach sixty-four centres covering 94% of US transplants.
The company is also progressing its clinical pipeline. It finalised the Phase 3 protocol for expanding Ryoncil® into adult treatment for steroid-refractory acute graft versus host disease and is scaling up manufacturing for its next-generation therapy, rexlemestrocel-L.
What did Mesoblast management say?
Mesoblast Chief Executive Dr Silviu Itescu said:
Today we report strong operational and financial performance for the first half of FY2026, a period that marks an important inflection point in Mesoblast's evolution from clinical development to sustainable commercial execution. Sales momentum for Ryoncil® continued to build, driving meaningful revenue and reinforcing the product's value in addressing significant unmet medical need and the strength of our commercial strategy. Importantly, we have improved the Company's financial position with positive cash flow generated from Ryoncil® sales, disciplined cost management, and a strategic refinancing, providing greater flexibility to support expansion and late-stage clinical programs. As we enter the second half of FY2026, we remain focused on accelerating commercial uptake, advancing regulatory and label expansion opportunities, and maintaining financial discipline to deliver sustainable long-term shareholder value.
What's next for Mesoblast?
Looking ahead, Mesoblast expects continued revenue momentum as Ryoncil® gains traction in the US market. The company remains focussed on onboarding additional transplant centres, increasing patient access, and expanding the approved uses for Ryoncil® into broader inflammatory conditions.
Beyond Ryoncil®, work continues on rexlemestrocel-L for chronic low back pain and advanced heart failure, with pivotal US trials nearing completion and regulatory filings expected in the coming months. Management is aiming for sustainable growth through product lifecycle extensions and new approvals.
Mesoblast share price snapshot
Over the past 12 months, Mesoblast shares have declined 2%, trailing the S&P/ASX 200 Index (ASX: XJO) which has risen 11% over the same period.
